REFERENCES
1. Dummer R, Robert C, Scolyer RA, et al. Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial. Nat Med. 2025;31:144-51.
2. Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:1465-77.
3. Long GV, Carlino MS, McNeil C, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024;35:1191-9.
4. Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107:112-22.
5. Bock AM, Epperla N. Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: recent advances and emerging therapies. J Hematol Oncol. 2025;18:68.
6. Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9:eadf3700.
7. Ellingsen EB, O’Day S, Mezheyeuski A, et al. Clinical activity of combined telomerase vaccination and pembrolizumab in advanced melanoma: results from a phase I trial. Clin Cancer Res. 2023;29:3026-36.
8. Ling AL, Solomon IH, Landivar AM, et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023;623:157-66.
9. Patel S, Dave K, Garcia MJ, Gongora CA, Travin MI, Zhang L. Multimodal imaging of immune checkpoint inhibitor myocarditis. J Clin Med. 2025;14:2850.
10. Chen Y, Ye Z, He RQ, Chen G, Zhang DX. Landscape of non-coding RNAs in cancer treatment-induced cardiovascular toxicity: from mechanistic insights to clinical implications. Semin Cancer Biol. 2025;115:16-39.
11. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-68.
12. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13:195-207.
13. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721-8.
14. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709-17.
15. Yu J, Zhang Y, Wang C, Yang W, Chen F. Associations between immune-related adverse events and the effectiveness of immunotherapeutic agents in advanced melanoma: a systematic review and meta-analysis. Dermatol Sin. 2025;43:107-15.
16. Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43:665-79.
17. Zhou Y, Wei Y, Tian X, Wei X. Cancer vaccines: current status and future directions. J Hematol Oncol. 2025;18:18.
18. Chowaniec H, Ślubowska A, Mroczek M, et al. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy. Front Immunol. 2024;15:1375433.
19. Gaál Z. Role of microRNAs in immune regulation with translational and clinical applications. Int J Mol Sci. 2024;25:1942.
20. Chodurska B, Kunej T. Long non-coding RNAs in humans: classification, genomic organization and function. Noncoding RNA Res. 2025;11:313-27.
21. Wang Y, Peng Z, Wang Y, et al. Immune microenvironment change and involvement of circular RNAs in TIL cells of recurrent nasopharyngeal carcinoma. Front Cell Dev Biol. 2021;9:722224.
22. Yuan X, Shen Q, Ma W. Long noncoding RNA hotair promotes the progression and immune escape in laryngeal squamous cell carcinoma through microRNA-30a/GRP78/PD-L1 axis. J Immunol Res. 2022;2022:5141426.
23. Wang J, Zhao X, Wang Y, et al. circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma. Cell Death Dis. 2020;11:32.
24. Chang X, Zhao J, Zhou Y, et al. MiR-7 deficiency promotes Th1 polarization of CD4+ T cells and enhances the antitumor effect in adoptive cell therapy for lung cancer. Immunol Res. 2024;72:134-46.
25. He J, Huang Z, He M, et al. Circular RNA MAPK4 (circ-MAPK4) inhibits cell apoptosis via MAPK signaling pathway by sponging miR-125a-3p in gliomas. Mol Cancer. 2020;19:17.
26. Feng Y, Zhang L, Wu J, et al. CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway. J Exp Clin Cancer Res. 2019;38:54.
27. Zhang Z, Lan H, Zhao S. LINC00467 enhanced the proliferative, migratory and invasive ability of breast cancer cells by targeting miR-18a/b-5p/MAPK4 axis. Cell Mol Biol. 2023;69:88-93.
28. Du SY, Huang XX, Li NM, et al. MiR-127-3p inhibits proliferation of ovarian cancer in rats through down-regulating MAPK4. Eur Rev Med Pharmacol Sci. 2020;24:10383-90.
29. Sun J, Jia H, Bao X, et al. Tumor exosome promotes Th17 cell differentiation by transmitting the lncRNA CRNDE-h in colorectal cancer. Cell Death Dis. 2021;12:123.
30. Zhao Y, Yu Z, Ma R, et al. lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migration. Mol Ther Nucleic Acids. 2021;23:536-51.
31. Li J, Wang K, Yang C, et al. Tumor-associated macrophage-derived exosomal LINC01232 induces the immune escape in glioma by decreasing surface MHC-I expression. Adv Sci. 2023;10:e2207067.
32. Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270-4.
33. Herault A, Mak J, de la Cruz-Chuh J, et al. NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity. Cancer Immunol Immunother. 2024;73:209.
34. MacNabb BW, Tumuluru S, Chen X, et al. Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing. Immunity. 2022;55:982-97.e8.
35. Zhang H, Li S, Wang D, et al. Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment. Biomark Res. 2024;12:96.
36. Zhang L, Xu X, Su X. Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application. Mol Cancer. 2020;19:48.
37. Wang Y, Zhao Y, Guo W, et al. Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response. Sci Adv. 2022;8:eadd0005.
38. Farooqi AA, Shepetov AM, Rakhmetova V, et al. Interplay between JAK/STAT pathway and non-coding RNAs in different cancers. Noncoding RNA Res. 2024;9:1009-22.
39. Vaxevanis C, Bachmann M, Seliger B. Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy. J Immunother Cancer. 2024;12:e009774.
40. Yang F, Chen Y, Luo L, Nong S, Li T. circFOXO3 induced by KLF16 modulates clear cell renal cell carcinoma growth and natural killer cell cytotoxic activity through sponging miR-29a-3p and miR-122-5p. Dis Markers. 2022;2022:6062236.
41. Tang Y, Cui G, Liu H, et al. Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells. Cancer Commun. 2024;44:601-36.
42. Yin Y, Cai X, Chen X, et al. Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res. 2014;24:1164-80.
43. Zheng Z, Xu PP, Wang L, et al. MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells. J Exp Clin Cancer Res. 2017;36:82.
44. Soheilifar MH, Vaseghi H, Seif F, et al. Concomitant overexpression of mir-182-5p and mir-182-3p raises the possibility of IL-17-producing Treg formation in breast cancer by targeting CD3d, ITK, FOXO1, and NFATs: a meta-analysis and experimental study. Cancer Sci. 2021;112:589-603.
45. Xiong G, Yang L, Chen Y, Fan Z. Linc-POU3F3 promotes cell proliferation in gastric cancer via increasing T-reg distribution. Am J Transl Res. 2015;7:2262-9.
46. Correia de Sousa M, Calo N, Sobolewski C, et al. Mir-21 suppression promotes mouse hepatocarcinogenesis. Cancers. 2021;13:4983.
47. Liu C, Liu R, Wang B, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021;9:e001895.
48. Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241.
49. Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019;26:3009-25.
50. Willsmore ZN, Coumbe BGT, Crescioli S, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. Eur J Immunol. 2021;51:544-56.
51. Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20:44.
52. Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14:45.
53. Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143:113365.
54. Wu X, Zhu Z, Zhang J, Tian M, Zhao P. Progress in understanding the regulatory mechanisms of immune checkpoint proteins PD-1 and PD-L1 expression. Clin Transl Oncol. 2025;27:3261-71.
55. Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550.
56. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767-78.
57. Patsoukis N, Duke-Cohan JS, Chaudhri A, et al. Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Commun Biol. 2020;3:128.
59. Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10.
60. Liao D, Wang M, Liao Y, Li J, Niu T. A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. Front Pharmacol. 2019;10:609.
61. Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975.
62. Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers. 2021;13:1440.
63. Van Coillie S, Wiernicki B, Xu J. Molecular and cellular functions of CTLA-4. Adv Exp Med Biol. 2020;1248:7-32.
64. Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332:600-3.
65. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229:12-26.
66. Wei J, Li W, Zhang P, Guo F, Liu M. Current trends in sensitizing immune checkpoint inhibitors for cancer treatment. Mol Cancer. 2024;23:279.
68. Hu Q, Ye Y, Chan LC, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019;20:835-51.
69. Martinez-Castillo M, Elsayed AM, López-Berestein G, Amero P, Rodríguez-Aguayo C. An overview of the immune modulatory properties of long non-coding RNAs and their potential use as therapeutic targets in cancer. Noncoding RNA. 2023;9:70.
70. Yu X, Zhang Y, Luo F, Zhou Q, Zhu L. The role of microRNAs in the gastric cancer tumor microenvironment. Mol Cancer. 2024;23:170.
71. Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19:287-305.
72. Qiu J, Zhong F, Zhang Z, et al. Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1α mRNA stability. Int Immunopharmacol. 2024;136:112415.
73. Lin Q, Liu T, Wang X, et al. Long noncoding RNA HITT coordinates with RGS2 to inhibit PD-L1 translation in T cell immunity. J Clin Invest. 2023;133:e162951.
74. Sun Z, Mai H, Xue C, et al. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination. J Immunother Cancer. 2023;11:e007415.
75. Ashizawa M, Okayama H, Ishigame T, et al. miRNA-148a-3p regulates immunosuppression in DNA mismatch repair-deficient colorectal cancer by targeting PD-L1. Mol Cancer Res. 2019;17:1403-13.
76. Huang J, Weng Q, Shi Y, et al. MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma. FEBS Open Bio. 2020;10:1065-71.
77. Miliotis C, Slack FJ. miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer. Cancer Lett. 2021;518:115-26.
78. Dong LF, Chen FF, Fan YF, Zhang K, Chen HH. circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape. J Immunother Cancer. 2023;11:e005461.
79. Chen QH, Li B, Liu DG, Zhang B, Yang X, Tu YL. LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1. Cancer Cell Int. 2020;20:394.
80. Zhang G, Li N, Li Z, et al. microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: a mechanism for regulating PD-1 expression and function in HBV-associated liver diseases. Oncotarget. 2015;6:18933-44.
81. Cheng S, Li F, Qin H, et al. Long noncoding RNA lncNDEPD1 regulates PD-1 expression via miR-3619-5p in CD8+ T cells. J Immunol. 2022;208:1483-92.
83. Wei J, Nduom EK, Kong LY, et al. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2016;18:639-48.
84. Vaddi PK, Osborne DG, Nicklawsky A, et al. CTLA4 mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood CTLA4 levels are associated with poor prognosis in metastatic melanoma patients. Front Immunol. 2023;14:1173035.
85. Li L, Yang L, Jiang D. Research progress of CD80 in the development of immunotherapy drugs. Front Immunol. 2024;15:1496992.
86. Wu R, Li F, Zhu J, et al. A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population. Med Oncol. 2014;31:60.
87. Miao Y, Yang H, Levorse J, et al. Adaptive immune resistance emerges from tumor-initiating stem cells. Cell. 2019;177:1172-86.e14.
88. Xu S, Tao Z, Hai B, et al. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun. 2016;7:11406.
89. Xu Z, Chen Y, Ma L, et al. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. Mol Ther. 2022;30:3133-54.
90. Zhang Y, Li Z, Chen M, et al. lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer. Breast Cancer. 2020;27:573-85.
91. Peng L, Chen Z, Chen Y, Wang X, Tang N. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Cancer Med. 2019;8:7161-73.
92. Le P, Romano G, Nana-Sinkam P, Acunzo M. Non-coding RNAs in cancer diagnosis and therapy: focus on lung cancer. Cancers. 2021;13:1372.
93. Gitto SB, Ihewulezi CJN, Powell DJ Jr. Adoptive T cell therapy for ovarian cancer. Gynecol Oncol. 2024;186:77-84.
94. Huang R, Li X, He Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13:86.
95. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331-42.
96. Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C. From concept to cure: the evolution of CAR-T cell therapy. Mol Ther. 2025;33:2123-40.
97. Umut Ö, Gottschlich A, Endres S, Kobold S. CAR T cell therapy in solid tumors: a short review. Memo. 2021;14:143-9.
98. Chen Y, Ye Z, Cho WC, Zhang DX. Cell avidity in CAR-T cell therapy. Expert Rev Mol Diagn. 2025;25:737-40.
99. Kerkar SP, Muranski P, Kaiser A, et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010;70:6725-34.
100. Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257:83-90.
101. Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019;20:1283.
102. Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18:842-59.
103. Kumar A, Watkins R, Vilgelm AE. Cell therapy with TILs: training and taming T cells to fight cancer. Front Immunol. 2021;12:690499.
104. Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387:2113-25.
105. Zhao Q, Jiang Y, Xiang S, et al. Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons. Front Immunol. 2021;12:658753.
106. Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5365-86.
107. Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36-50.
108. Chen Y, Yu Z, Tan X, et al. CAR-macrophage: a new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021;139:111605.
109. Chen K, Liu ML, Wang JC, Fang S. CAR-macrophage versus CAR-T for solid tumors: the race between a rising star and a superstar. Biomol Biomed. 2024;24:465-76.
110. Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947-53.
111. Niu Z, Chen G, Chang W, et al. Chimeric antigen receptor-modified macrophages trigger systemic anti-tumour immunity. J Pathol. 2021;253:247-57.
112. Morrissey MA, Williamson AP, Steinbach AM, et al. Chimeric antigen receptors that trigger phagocytosis. Elife. 2018;7:e36688.
113. Zeng Q, Zhang S, Leng N, Xing Y. Advancing tumor vaccines: overcoming TME challenges, delivery strategies, and biomaterial-based vaccine for enhanced immunotherapy. Crit Rev Oncol Hematol. 2025;205:104576.
114. Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol. 2021;52:101481.
115. Hato L, Vizcay A, Eguren I, et al. Dendritic cells in cancer immunology and immunotherapy. Cancers. 2024;16:981.
116. Heras-Murillo I, Adán-Barrientos I, Galán M, Wculek SK, Sancho D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024;21:257-77.
117. Kantoff PW, Higano CS, Shore ND, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
118. Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237-53.
119. Yi M, Li T, Niu M, et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Ther. 2024;9:176.
120. Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021;21:481-99.
122. Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160-77.
123. Rahman MM, McFadden G. Oncolytic viruses: newest frontier for cancer immunotherapy. Cancers. 2021;13:5452.
124. Liu X, Zhuang Y, Huang W, et al. Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy. Nat Commun. 2023;14:4106.
125. Teng Z, Lin X, Luan C, Sun Y, Li X. The high expression of miR-564 in patients with systemic lupus erythematosus promotes differentiation and maturation of DC cells by negatively regulating TP53 expression in vitro. Lupus. 2021;30:1469-80.
126. Zhang Z, Zhang C, Li F, Zhang B, Zhang Y. Regulation of memory CD8+ T cell differentiation by microRNAs. Cell Physiol Biochem. 2018;47:2187-98.
127. Hines MJ, Coffre M, Mudianto T, et al. miR-29 sustains B cell survival and controls terminal differentiation via regulation of PI3K signaling. Cell Rep. 2020;33:108436.
128. Galore-Haskel G, Greenberg E, Yahav I, et al. microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy. Cancer Immunol Immunother. 2021;70:1541-55.
129. Lin YZ, Liu CH, Wu WR, et al. Memory-promoting function of miR-379-5p attenuates CD8+ T cell exhaustion by targeting immune checkpoints. J Immunother Cancer. 2025;13:e010363.
130. Zhang J, Zhu J, Zheng G, et al. Co-expression of miR155 or LSD1 shRNA increases the anti-tumor functions of CD19 CAR-T cells. Front Immunol. 2021;12:811364.
131. Yang LR, Li L, Meng MY, et al. IL-7 promotes CD19-directed CAR-T cells proliferation through miRNA-98-5p by targeting CDKN1A. Int Immunopharmacol. 2023;124:110974.
132. Casanova-Acebes M, Dalla E, Leader AM, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature. 2021;595:578-84.
133. Lan C, Huang X, Lin S, et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 2013;12:259-67.
134. Cao L, Che X, Qiu X, et al. M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer. Cancer Manag Res. 2019;11:6125-38.
135. Zhang Y, Wang H, Xu X, et al. Poor prognosis and therapeutic responses in LILRB1-expressing M2 macrophages-enriched gastric cancer patients. Front Oncol. 2021;11:668707.
136. Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res. 2025;44:145.
137. Bai T, Li P, Liu Y, et al. Knockdown of miR-411-3p induces M2 macrophage polarization and promotes colorectal cancer progression by regulation of MMP7. Eur J Histochem. 2025;69:4178.
138. Tu X, Lin W, Zhai X, et al. Oleanolic acid inhibits M2 macrophage polarization and potentiates anti-PD-1 therapy in hepatocellular carcinoma by targeting miR-130b-3p-PTEN-PI3K-Akt signaling and glycolysis. Phytomedicine. 2025;141:156750.
139. Wang Q, Sun Z, Guo J, et al. Tumor-derived exosomal LINC01812 induces M2 macrophage polarization to promote perineural invasion in cholangiocarcinoma. Cancer Lett. 2025;617:217596.
140. Zhang Y, Fu J, Shi Y, et al. A new cancer immunotherapy via simultaneous DC-mobilization and DC-targeted IDO gene silencing using an immune-stimulatory nanosystem. Int J Cancer. 2018;143:2039-52.
141. Zhang M, Shi Y, Zhang Y, et al. miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy. Cancer Immunol Immunother. 2020;69:951-67.
142. Hodge J, Wang F, Wang J, et al. Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer. Oncoimmunology. 2020;9:1724761.
143. Zhao Y, Jia Y, Wang J, et al. circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis. Mol Cancer. 2024;23:47.
144. Afra F, Mahboobipour AA, Salehi Farid A, Ala M. Recent progress in the immunotherapy of hepatocellular carcinoma: non-coding RNA-based immunotherapy may improve the outcome. Biomed Pharmacother. 2023;165:115104.
145. Kundu ST, Rodriguez BL, Gibson LA, et al. The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response. Genes Dev. 2022;36:582-600.
146. Dellalibera-Joviliano R, Garcia ME, Marins M, et al. Interleukin-12 treatment reduces tumor growth and modulates the expression of CASKA and MIR-203 in athymic mice bearing tumors induced by the HGC-27 gastric cancer cell line. Pathol Res Pract. 2024;263:155625.
147. Taghikhani A, Hassan ZM, Ebrahimi M, Moazzeni SM. microRNA modified tumor-derived exosomes as novel tools for maturation of dendritic cells. J Cell Physiol. 2019;234:9417-27.
148. Singh HM, Leber MF, Bossow S, et al. MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. Mol Ther Oncolytics. 2021;21:340-55.
149. Jennings VA, Rumbold-Hall R, Migneco G, et al. Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment. Front Immunol. 2024;15:1500570.
150. Jalalvand M, Darbeheshti F, Rezaei N. Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer. Immunotherapy. 2021;13:587-603.
151. Sun Q, Liu X, Peng Q, Hu L, Jiang X. ncRNA-mediated high expression of LPCAT1 correlates with poor prognosis and tumor immune infiltration of liver hepatocellular carcinoma. J Immunol Res. 2022;2022:1584397.
152. Miao Z, Li J, Wang Y, et al. Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC axis and PD-L1 phosphorylation. Mol Cancer. 2023;22:205.
153. Gao X, Tang M, Tian S, et al. ncRNAs-mediated TIMELESS overexpression in lung adenocarcinoma correlates with reduced tumor immune cell infiltration and poor prognosis. PLoS ONE. 2024;19:e0296829.
154. Liu L, Yi H, Wang C, et al. Integrated nanovaccine with microRNA-148a inhibition reprograms tumor-associated dendritic cells by modulating miR-148a/DNMT1/SOCS1 axis. J Immunol. 2016;197:1231-41.
155. Ye Z, Ye S, Yin Z, et al. lncRNA ENST000000454471 promotes lung adenocarcinoma progression and tumor immune escape: protein structure and biological functions of histone deacetylase 8. Int J Biol Macromol. 2025;303:140664.
156. Huang D, Chen J, Yang L, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018;19:1112-25.
157. Bao H, Jiang Y, Wang N, Su H, Han X. Long noncoding RNAs MALAT1 and HOTTIP act as serum biomarkers for hepatocellular carcinoma. Cancer Control. 2024;31:10732748241284821.
158. Zhao X, Zhong Y, Wang X, Shen J, An W. Advances in circular RNA and its applications. Int J Med Sci. 2022;19:975-85.
159. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384-8.
160. Zhou WY, Cai ZR, Liu J, Wang DS, Ju HQ, Xu RH. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19:172.
161. Jiang W, Pan S, Chen X, Wang ZW, Zhu X. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy. Mol Cancer. 2021;20:116.
162. Li Y, Ye J, Xu S, Wang J. Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC. Discov Oncol. 2023;14:142.
163. Han Z, Liu W, Zhu Y, et al. Non-coding RNAs in gastric cancer: mechanisms and therapeutic prospects. Mol Cancer. 2025;24:244.
164. Ding Z, Li R, Han J, Sun D, Shen L, Wu G. Identification of an immune-related LncRNA signature in gastric cancer to predict survival and response to immune checkpoint inhibitors. Front Cell Dev Biol. 2021;9:739583.
165. Li X, Wang S, Cui Y, et al. CircRNA signature predicts immunotherapy response in advanced non-small cell lung cancer. Ther Adv Med Oncol. 2025;17:17588359251395920.
166. Roy S, Kanda M, Nomura S, et al. Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer. Mol Cancer. 2022;21:42.
167. Weidhaas JB, McGreevy KM, Marco N, et al. Germline microRNA-based signatures predict toxicity and response to anti-CTLA-4 therapy. J Transl Med. 2025;23:848.
168. Liu Y, Chen J, Yang D, et al. Machine learning combined with multi-omics to identify immune-related LncRNA signature as biomarkers for predicting breast cancer prognosis. Sci Rep. 2025;15:23863.
169. Liu J, Zhou WY, Luo XJ, et al. Long noncoding RNA regulating ImMune escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma. Clin Transl Med. 2023;13:e1410.
170. Bender M, Chen I, Bluhm L, Mohr P, Volkmer B, Greinert R. LASSO logistic regression reveals a mixed MiRNA and serum-marker classifier for prediction of immunotherapy response in liquid biopsies of melanoma patients. EJC Skin Cancer. 2024;2:100260.
171. Xu G, Ji Y, Wang L, et al. M6A-related long non-coding RNA displays utility in predicting prognosis, portraying the tumor immune microenvironment and guiding immunotherapy in pancreatic ductal adenocarcinoma. Vaccines. 2023;11:499.
172. Saini S, Gadet JAMA, Freeman GJ, Chiocca EA, Mineo M. Improving IL12 immunotherapy in glioblastoma by targeting the long noncoding RNA INCR1. J Neurooncol. 2025;173:205-16.
173. Ma Y, Li J, Zhao Y, Hu B, Liu Y, Liu C. Nanobubble-mediated co-delivery of Ce6 and miR-195 for synergized sonodynamic and checkpoint blockade combination therapy with elicitation of robust immune response in hepatocellular carcinoma. Eur J Pharm Biopharm. 2022;181:36-48.
174. Dai W, Qiao X, Fang Y, et al. Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduct Target Ther. 2024;9:332.
175. Fu Y, Mackowiak B, Feng D, et al. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. Gut. 2023;72:1942-58.
176. Zhang C, Wei S, Dai S, et al. The NR_109/FUBP1/c-Myc axis regulates TAM polarization and remodels the tumor microenvironment to promote cancer development. J Immunother Cancer. 2023;11:e006230.
177. Zhou JG, Liang R, Wang HT, et al. Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients - knowledge from two independent international studies. Neoplasia. 2023;37:100877.
178. Choi JY, Seok HJ, Lee DH, et al. Tumor-derived miR-6794-5p enhances cancer growth by promoting M2 macrophage polarization. Cell Commun Signal. 2024;22:190.
179. Wei S, Wang K, Huang X, Zhao Z, Zhao Z. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis. Int J Immunopathol Pharmacol. 2019;33:2058738419859699.
180. Hirata H, Hinoda Y, Shahryari V, et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res. 2015;75:1322-31.
181. Fan Y, Shen B, Tan M, et al. TGF-β-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin Cancer Res. 2014;20:1531-41.
182. Kwok ZH, Roche V, Chew XH, Fadieieva A, Tay Y. A non-canonical tumor suppressive role for the long non-coding RNA MALAT1 in colon and breast cancers. Int J Cancer. 2018;143:668-78.
183. Kim J, Piao HL, Kim BJ, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018;50:1705-15.
184. Wang X, Sehgal L, Jain N, Khashab T, Mathur R, Samaniego F. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. J Transl Med. 2016;14:346.
185. Li F, Li X, Qiao L, Liu W, Xu C, Wang X. MALAT1 regulates miR-34a expression in melanoma cells. Cell Death Dis. 2019;10:389.
186. Luan W, Li L, Shi Y, et al. Long non-coding RNA MALAT1 acts as a competing endogenous RNA to promote malignant melanoma growth and metastasis by sponging miR-22. Oncotarget. 2016;7:63901-12.
187. Tang D, Yang Z, Long F, et al. Long noncoding RNA MALAT1 mediates stem cell-like properties in human colorectal cancer cells by regulating miR-20b-5p/Oct4 axis. J Cell Physiol. 2019;234:20816-28.
188. Chen Q, Zhu C, Jin Y. The oncogenic and tumor suppressive functions of the long noncoding RNA MALAT1: an emerging controversy. Front Genet. 2020;11:93.
189. Zhang PF, Pei X, Li KS, et al. Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Mol Cancer. 2019;18:179.
190. Zhao L, Liu Y, Zhang J, Liu Y, Qi Q. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death Dis. 2019;10:731.
191. Dong Y, Gao Q, Chen Y, et al. Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy. Nat Commun. 2023;14:2540.
192. Wang P, Xue Y, Han Y, et al. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science. 2014;344:310-3.
193. Pang KC, Dinger ME, Mercer TR, et al. Genome-wide identification of long noncoding RNAs in CD8+ T cells. J Immunol. 2009;182:7738-48.
194. Yu T, Zuo QF, Gong L, Wang LN, Zou QM, Xiao B. MicroRNA-491 regulates the proliferation and apoptosis of CD8+ T cells. Sci Rep. 2016;6:30923.
195. Li Q, Johnston N, Zheng X, et al. miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget. 2016;7:53735-50.
196. Hossam Abdelmonem B, Kamal LT, Wardy LW, et al. Non-coding RNAs: emerging biomarkers and therapeutic targets in cancer and inflammatory diseases. Front Oncol. 2025;15:1534862.
197. Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating non-coding RNAs - an update. Nat Rev Clin Oncol. 2018;15:541-63.
198. Abu N, Jamal R. Circular RNAs as promising biomarkers: a mini-review. Front Physiol. 2016;7:355.
199. Yang P, Cao X, Cai H, et al. Upregulation of microRNA-155 enhanced migration and function of dendritic cells in three-dimensional breast cancer microenvironment. Immunol Investig. 2021;50:1058-71.
200. Badowski C, He B, Garmire LX. Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty. NPJ Precis Oncol. 2022;6:40.
201. Cheong JK, Rajgor D, Lv Y, Chung KY, Tang YC, Cheng H. Noncoding RNome as enabling biomarkers for precision health. Int J Mol Sci. 2022;23:10390.
202. Yang LX, Li H, Cheng ZH, et al. The application of non-coding RNAs as biomarkers, therapies, and novel vaccines in diseases. Int J Mol Sci. 2025;26:3055.
203. Jenike AE, Halushka MK. miR-21: a non-specific biomarker of all maladies. Biomark Res. 2021;9:18.
204. Grillone K, Caridà G, Luciano F, et al. A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer. J Transl Med. 2024;22:731.
205. Li J, Zhao L, Li L, et al. Urine exosomal lncRNAs as novel biomarkers for early diagnosis of bladder cancer based on microarray differential expression profiling. Int J Biol Markers. 2025;40:24-34.
206. De Gregorio A, Sacconi A, Mandoj C, et al. Development of an innovative duplex digital PCR assay for circulating miRNA ratio quantification in metastatic melanoma. J Transl Med. 2025;23:904.
207. He XX, Chang Y, Meng FY, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357-69.
208. Chai X, Wu S, Shen Q, Huang Q. Advances in expression regulation, molecular targeting mechanisms, and therapeutic applications of the Let-7 microRNA family in gastric cancer. Oncol Res. 2025;33:3731-52.
209. Chen L, Li Q, Jiang Z, et al. Chrysin induced cell apoptosis through H19/let-7a/COPB2 axis in gastric cancer cells and inhibited tumor growth. Front Oncol. 2021;11:651644.
210. Zhang Z, Zhang J, Diao L, Han L. Small non-coding RNAs in human cancer: function, clinical utility, and characterization. Oncogene. 2021;40:1570-7.
211. Mu D, Han B, Huang H, Zheng Y, Zhang J, Shi Y. Unraveling the advances of non-coding RNAs on the tumor microenvironment: innovative strategies for cancer therapies. J Transl Med. 2025;23:614.
212. Kiaie SH, Majidi Zolbanin N, Ahmadi A, et al. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnol. 2022;20:276.
213. Seok H, Lee H, Jang ES, Chi SW. Evaluation and control of miRNA-like off-target repression for RNA interference. Cell Mol Life Sci. 2018;75:797-814.
214. Cai Z, Ma H, Ye F, et al. Discovery of RNA-targeting small molecules: challenges and future directions. MedComm. 2025;6:e70342.
215. Shi Y, Yu Q, Tan L, Wang Q, Zhu WH. Tumor microenvironment-responsive polymer delivery platforms for cancer therapy. Angew Chem Int Ed Engl. 2025;64:e202503776.
216. Si J, Su X, Jin Z, Duan S. Uncovering essential lncRNAs through transcriptome-scale CRISPR-Cas13 screening. Adv Biotechnol. 2025;3:27.
217. Tsahouridis O, Xu M, Song F, Savoldo B, Dotti G. The landscape of CAR-engineered innate immune cells for cancer immunotherapy. Nat Cancer. 2025;6:1145-56.
218. Ghasemi A, Martinez-Usatorre A, Liu Y, et al. Dendritic cell progenitors engineered to express extracellular-vesicle-internalizing receptors enhance cancer immunotherapy in mouse models. Nat Commun. 2025;16:9148.
219. Golinelli G, Scholler J, Roussel-Gervais A, et al. Multiplex engineering using microRNA-mediated gene silencing in CAR T cells. Front Immunol. 2025;16:1647433.
220. Hao J, Li Y, Huang L, et al. Smart nanoarchitectures for precision RNA delivery: harnessing endogenous and exogenous stimuli in cancer treatment. Theranostics. 2025;15:7747-78.
221. Di Ianni E, Obuchi W, Breyne K, Breakefield XO. Extracellular vesicles for the delivery of gene therapy. Nat Rev Bioeng. 2025;3:360-73.
222. Lu LF, Thai TH, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 2009;30:80-91.
223. Rabaan AA, AlSaihati H, Bukhamsin R, et al. Application of CRISPR/Cas9 technology in cancer treatment: a future direction. Curr Oncol. 2023;30:1954-76.
224. Hussen BM, Rasul MF, Abdullah SR, et al. Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges. Mil Med Res. 2023;10:32.
225. Wang H, Yuan Y, Qin L, et al. Tunable rigidity of PLGA shell-lipid core nanoparticles for enhanced pulmonary siRNA delivery in 2D and 3D lung cancer cell models. J Control Release. 2024;366:746-60.
226. Zhang Q, Yan S, Yan X, Lv Y. Recent advances in metal-organic frameworks: synthesis, application and toxicity. Sci Total Environ. 2023;902:165944.
227. Cao X, Cai Z, Zhang J, Zhao F. Engineering circular RNA medicines. Nat Rev Bioeng. 2024;3:270-87.
228. Coan M, Haefliger S, Ounzain S, Johnson R. Targeting and engineering long non-coding RNAs for cancer therapy. Nat Rev Genet. 2024;25:578-95.
229. Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16:748-59.
230. Luisotti L, Germelli L, Piccarducci R, Giacomelli C, Marchetti L, Martini C. Extracellular vesicles as vehicles for small non-coding RNA therapeutics: standardization challenges for clinical translation. Extracell Vesicles Circ Nucl Acids. 2025;6:403-32.
231. Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater. 2023;35:e2303261.
232. Tili E, Michaille JJ, Croce CM. miR-155 aberrant expression impairs tumor rejection because of its targeting of ICOSL and multiple pathways implicated in the antitumor response. Pharmacol Rev. 2026;78:100088.
233. Jia Q, Wang A, Yuan Y, Zhu B, Long H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol. 2022;11:24.
234. Gareev I, de Jesus Encarnacion Ramirez M, Goncharov E, et al. MiRNAs and lncRNAs in the regulation of innate immune signaling. Noncoding RNA Res. 2023;8:534-41.
235. Zhou H, Sun C, Li C, et al. The microRNA-106a/20b strongly enhances the antitumour immune responses of dendritic cells pulsed with glioma stem cells by targeting STAT3. J Immunol Res. 2022;2022:9721028.
236. Wang Z, Li X, Zhang S, et al. The SMIM25-COX-2 axis modulates the immunosuppressive tumor microenvironment and predicts immunotherapy response in hepatocellular carcinoma. Curr Issues Mol Biol. 2025;47:693.
237. Gao Y, Wang X, Dong L, et al. Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers. Sci Data. 2023;10:663.
238. Liu Z, Gao L, Cheng L, et al. The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: classification, mechanisms, and potential therapeutic implications. Exp Mol Med. 2023;55:487-501.
239. Fosseprez O, Cuvier O. Uncovering the functions and mechanisms of regulatory elements-associated non-coding RNAs. Biochim Biophys Acta Gene Regul Mech. 2024;1867:195059.
240. Wang X, Barrera C, Bera K, et al. Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors. Sci Adv. 2022;8:eabn3966.
241. Ding Y, Wang Y, Hu Q. Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. Exploration. 2022;2:20210106.
242. Wu X, Xu W, Lin D, Sun L, Dai J, Cao G. A guide for spatial omics technologies: innovation, evaluation, and application. Adv Sci. 2026:e20806.
243. Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther. 2022;7:121.
244. Du F, Tang L, Wang F, et al. Epigenetic modification of cuproptosis by non-coding RNAs in cancer drug resistance. Mol Cancer. 2025;24:230.
245. Albakr L, Alqahtani FY, Aleanizy FS, et al. Improved delivery of miR-1296 loaded cationic nanoliposomes for effective suppression of triple negative breast cancer. Saudi Pharm J. 2021;29:446-55.
